PolycapTM is a capsule or pill developed by Cadila Pharmaceuticals Ltd. India. The pill is a combination of Atenolol (50 mg), Hydrochlorothiazide (12·5 mg), Ramipril (5 mg), Simvastatin (20 mg) and Aspirin (100 mg) for primary prevention of cardiovascular events and stroke.
According to Cadila Pharmaceuticals commissioned and sponsored ‘The Indian PolycapTM Study’ PolycapTM brings down the risk of coronary heart disease by 62% and stroke by 48%. PolycapTM can reduce multiple risk factors for cardiovascular diseases such as lowering the blood pressure, the heart rate, the lipids and decreasing the stickiness of the platelets. ‘The polypill - can reduce cardiovascular events by more than 80% in healthy individuals.’ This was the conclusion of the study of the effect of the PolycapTM on blood pressure, lipids, heart rate, and urinary thromboxane B2, and of the assessment of its tolerability. Read More
They say Cadila Pharmaceuticals’ ‘PolycapTM’ is a pioneer. Some interesting facts are here.
Cadila Pharmaceuticals Ltd. is one of the largest privately held pharmaceutical companies in India, headquartered at Ahmedabad, in the State of Gujarat. Over the last six decades, the company has been developing and manufacturing pharmaceutical products in India and selling and distributing these in over eighty-five other countries around the world.
At Cadila Pharmaceuticals, Research and Development is at the core of all its initiatives, be it Biotechnology, APIs, Formulations, Plant Tissue Culture or Phytochemistry.
More than 300 scientists in its various Research and Development setups reinforce the competitiveness of research in the therapeutic areas which have high unmet medical needs.Read More
Medical and Scientific fraternity speak
"By combining these medications in one pill, it will make it easier for people to take their medication. However, it is important that more research and investigation is done into this pill to ensure its safety."
"Polypill will reduce the cost of the pills and it will improve compliance. We know that more people are apt taking one pill compared to five or six pills in a day."
“ That was a big surprise. I would have expected five times the number of people to have side effects," because of the possibility the drugs would interact and magnify any problems ”
Consult Cadila Pharmaceuticals’ Medical Expert Team
PolycapTM is indicated for Secondary Prevention of CVD as it contains following 5 proven and safe therapies commonly recommended and prescribed for secondary prevention.
- PolycapTM dose is 1-2 capsules once a day for CVD patients for Secondary Prevention.
- PolycapTM dose is 1 capsule once a day for Primary Prevention in patients at risk of CV events and stroke.